Mission Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, UK, focused on promoting the removal of dysfunctional mitochondria to restore cellular health. Its lead candidate, MTX325, inhibits the mitochondrial DUB enzyme USP30 and is being advanced for central-nervous-system disorders, with an upcoming Phase Ib proof-of-mechanism study in Parkinson’s disease patients. A second program, MTX652, targets peripheral indications using the same mitophagy-enhancing approach. Recent Phase Ia studies, including PET imaging, confirmed that MTX325 penetrates functional brain tissue in healthy volunteers, de-risking further clinical work. The company’s development efforts are additionally supported by a $5.2 million grant from the Michael J. Fox Foundation and Parkinson’s UK. Mission Therapeutics is led by Executive Director Dr. Anker Lundemose, Chief Development Officer Dr. Sarah J. Fritchley, and Chairman Dr. James B. Summers.

Total raised

$197M

Funding rounds

8

Latest round

Equity

Latest activity

Oct 2025